{"id":694,"date":"2018-05-03T11:30:40","date_gmt":"2018-05-03T09:30:40","guid":{"rendered":"https:\/\/www.fondationbarletta.org\/publications\/"},"modified":"2025-02-13T18:04:33","modified_gmt":"2025-02-13T17:04:33","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.fondationbarletta.org\/en\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

[et_pb_section fb_built=”1″ inner_shadow=”on” fullwidth=”on” _builder_version=”4.16″ background_color=”#2ea3f2″ z_index_tablet=”500″ collapsed=”off” global_colors_info=”{}”][et_pb_fullwidth_header title=”Publications” _builder_version=”4.16″ background_color=”rgba(255, 255, 255, 0)” background_image=”https:\/\/www.fondationbarletta.org\/wp-content\/uploads\/2019\/04\/pipette_jaugee-banner.jpg” max_width_tablet=”50px” z_index_tablet=”500″ global_colors_info=”{}” button_one_text_size__hover_enabled=”off” button_one_text_size__hover=”null” button_two_text_size__hover_enabled=”off” button_two_text_size__hover=”null” button_one_text_color__hover_enabled=”off” button_one_text_color__hover=”null” button_two_text_color__hover_enabled=”off” button_two_text_color__hover=”null” button_one_border_width__hover_enabled=”off” button_one_border_width__hover=”null” button_two_border_width__hover_enabled=”off” button_two_border_width__hover=”null” button_one_border_color__hover_enabled=”off” button_one_border_color__hover=”null” button_two_border_color__hover_enabled=”off” button_two_border_color__hover=”null” button_one_border_radius__hover_enabled=”off” button_one_border_radius__hover=”null” button_two_border_radius__hover_enabled=”off” button_two_border_radius__hover=”null” button_one_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover=”null” button_two_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover=”null” button_one_bg_color__hover_enabled=”off” button_one_bg_color__hover=”null” button_two_bg_color__hover_enabled=”off” button_two_bg_color__hover=”null”]<\/p>\n

[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”59px|1px|59.9479px|0px|false|false” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” link_option_url_new_window=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_accordion admin_label=”Accord\u00e9on” _builder_version=”4.27.4″ link_option_url_new_window=”on” hover_enabled=”0″ z_index_tablet=”500″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_accordion_item _builder_version=”4.27.4″ _module_preset=”default” title=”2024″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

*Cacciatore A, Shinde D, Musumeci C, et al. Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer. Nat Commun<\/em><\/strong>. 2024;15(1):6672. doi:10.1038\/s41467-024-50908-7<\/a>.
*Iseas S, Mariano G, Gros L, et al. Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances. Mol Diagn Ther<\/em><\/strong>. 2024;28(2):201-214. doi: 10.1007\/s40291-023-00692-9<\/a>.<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item _builder_version=”4.27.4″ _module_preset=”default” title=”2023″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n

*Cacciatore A, Albino D, Catapano CV, et al. Preclinical Models of Neuroendocrine Prostate Cancer. Curr Protoc<\/em><\/strong>. 2023;3(5): e742. doi:10.1002\/cpz1.742<\/a>.
*Iseas S, Prost D, Bouchereau S, et al. Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort. Biomedicines<\/em><\/strong>. 2023;11(3):791. doi: 10.3390\/biomedicines11030791<\/a>.<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2022″ open=”on” _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

*Bonfiglio F, Bruscaggin A, Guidetti F et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood<\/em><\/strong>. 2022; 139(5):732-747. doi: 10.1182\/blood.2021012386<\/a><\/p>\n

*Iseas S, Sendoya JM, Robbio J, et al. Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. Front Oncol<\/em><\/strong>. 2022 Jan 7;11:801880. doi: 10.3389\/fonc.2021.801880<\/a><\/p>\n

*Nuan-Aliman S, Bordereaux D, Thieblemont C, Baud V. The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells.\u00a0 Biomedicines<\/em><\/strong>. 2022;10(2):348. doi: 10.3390\/biomedicines10020348<\/a><\/p>\n

*Takenaka IKTM, Bartelli TF, Defelicibus A, et al. Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer. Front Oncol<\/em><\/strong>. 2022; 12: 809441. doi: 10.3389\/fonc.2022.809441<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2020″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

*Condoluci A,\u00a0Terzi di Bergamo L,\u00a0Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood<\/em><\/strong>. 2020;135(21):1859-1869. doi: 10.1182\/blood.2019003453<\/a><\/p>\n

*Evrard D, Hourseau M, Couvelard A, et al. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. Oncoimmunology<\/em><\/strong>. 2020;9(1):1844403. doi: 10.1080\/2162402X.2020.1844403<\/a>.<\/p>\n

*Glembotsky AC, Marin Oyarz\u00fan CP, De Luca G, et al . First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: correlation with the clinical phenotype. Haematologica<\/em><\/strong>. 2020;105(10):e535. \u00a0doi: 10.3324\/haematol.2020.253070<\/a><\/p>\n

*Golubicki M, Bonjoch L,Acu\u00f1a-Ochoa JG, et al. Germline biallelic Mcm8 variants are associated with early-onset Lynch-like syndrome. JCI Insight<\/em><\/strong>. 2020; 17;5(18):e140698. doi: 10.1172\/jci.insight.140698<\/a><\/p>\n

*Recondo G, Mahjoubi L, Maillard A, et al. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. NPJ Precis Oncol<\/em><\/strong>. 2020;4:27. doi: 10.1038\/s41698-020-00130-7<\/a>.<\/p>\n

*Sendoya JM, Iseas S, Coraglio M et al. Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers<\/strong> <\/em>(Basel). 2020; 12(8): 2227. doi: 10.3390\/cancers12082227<\/a><\/p>\n

*Tam C, Seymour JF. A predictive tool for early-stage CLL. Blood<\/em><\/strong>. 2020;135(21):1820-1821. doi: 10.1182\/blood.2020005426<\/a><\/p>\n

*Zugbi S, Ganiewich D, Bhattacharyya A, et al. Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. Cancers<\/em><\/strong> (Basel). 2020;22;12(9):2714. doi: 10.3390\/cancers12092714<\/a>.<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2021″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

*Aschero R, Francis JH, Ganiewich d, et al. Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers<\/em><\/strong> (Basel). 2021;13(4):673. doi: 10.3390\/cancers13040673<\/a><\/p>\n

*Bolis M, Bossi D, Vallerga A, et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun<\/strong><\/em>. 2021; 12: 7033. doi: 10.1038\/s41467-021-26840-5<\/a><\/p>\n

*Cancela MB, Zugbi S, Winter U, et al. A decision process for drug discovery in retinoblastoma. Invest New Drugs<\/em><\/strong>. 2021;39(2):426-441. doi: 10.1007\/s10637-020-01030-0<\/a><\/p>\n

*Formaggio N, Rubin MA, Theurillat JP, et al. Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene<\/em><\/strong>. 2021;40(7):1205-1216. doi: 10.1038\/s41388-020-01598-0<\/a>.<\/p>\n

*Golubicki M, D\u00edaz-Gay M, Bonjoch L, et al. Comprehensive Genomic Characterization of Fifteen Early-Onset Lynch-Like Syndrome Colorectal Cancers. Cancers<\/em><\/strong> (Basel). 2021; 12;13(6):1259. doi: 10.3390\/cancers13061259<\/a><\/p>\n

*Iseas S, Golubicki M, Robbio J, et al. A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma. Transl Oncol<\/em><\/strong>. 2021;14(6):101084. doi: 10.1016\/j.tranon.2021.101084<\/a><\/p>\n

*Liu J, Ottaviani D, Sefta M, et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal\/ganglion cell gene expression \u00a0Nat Commun<\/em><\/strong>. 2021; 12(1):5578. doi: 10.1038\/s41467-021-25792-0<\/a><\/p>\n

*Moia R, Favini C, Ferri V, et al. Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. Br J Haematol<\/strong><\/em>. 2021;195(1):108-112. doi: 10.1111\/bjh.17718<\/a><\/p>\n

*Winter U, Ganiewich D, Ottaviani D, et al. Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. JAMA Ophthalmol<\/em><\/strong>. 2021;138(5):569-574. doi: 10.1001\/jamaophthalmol.2020.0427<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2019″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Antelo M, Golubicki M, Roca E, et al. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer. Int J Cancer<\/em><\/strong>. 2019; 145(3):705-713. doi: 10.1002\/ijc.32160<\/a><\/p>\n

*Bellini A, Bessoltane-Bentahar N, Bhalshankar J, et al. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. Int J Cancer<\/strong><\/em>. 2019. doi: 10.1002\/ijc.32361<\/a><\/p>\n

*Evrard D, Szturz P, Tijeras-Raballand A, et al. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy. Oral Oncol<\/strong><\/em>. 2019; 88:29-38. doi: 10.1016\/j.oraloncology.2018.10.040<\/a><\/p>\n

*Glembotsky AC, Sliwa D, Bluteau D, et al. Downregulation of TREM-like transcript-1 and collagen receptor \u03b12 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia. Haematologica<\/strong><\/em> 2019;104(6):1244-1255. doi: 10.3324\/haematol.2018.188904<\/a><\/p>\n

*Jim\u00e9nez I, Chicard M, Colmet-Daage L, et al. Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. Int J Cancer<\/strong><\/em> 2019; 144(1):68-79. doi: 10.1002\/ijc.31620<\/a><\/p>\n

*Krisko A, Radman M. Protein damage, ageing and age-related diseases. Open Biol<\/strong><\/em>. 2019; 9(3):180249. doi: 10.1098\/rsob.180249<\/a><\/p>\n

*Nicolle R, Raffenne J, Paradis V, et al. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Cancers<\/strong><\/em> (Basel). 2019; 11(1). pii: E126. doi: 10.3390\/cancers11010126<\/a><\/p>\n

*Radman M. \u00a0Cellular parabiosis and the latency of age-related diseases. Open Biol<\/strong><\/em> 2019; 9(3):180250. doi: 10.1098\/rsob.180250<\/a><\/p>\n

*Winter U, Aschero R, Fuentes F, et al. Tridimensional Retinoblastoma Cultures as Vitreous Seeds Models for Live-Cell Imaging of Chemotherapy Penetration. Int J Mol Sci<\/strong><\/em>. 2019;20(5). doi: 10.3390\/ijms20051077<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2018″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Chicard M, Colmet-Daage L, Clement N et al. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clin Cancer Res<\/em><\/strong> 2018;24(4):939-949. doi: 10.1158\/1078-0432.CCR-17-1586<\/a><\/p>\n

*Cros J, Raffenne J, Couvelard A, et al. Tumor Heterogeneity in Pancreatic Adenocarcinoma. Pathobiology<\/em><\/strong>. 2018; 85(1-2):64-71. doi: 10.1159\/000477773<\/a><\/p>\n

*Depuydt P, Boeva V, Hocking TD, et al. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst<\/em><\/strong> 2018;110(10):1084-1093. doi: 10.1093\/jnci\/djy022<\/a><\/p>\n

*Deveau P, Colmet Daage L, Oldridge D, et al. QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics<\/em><\/strong> 2018;34(11):1808-1816. doi: 10.1093\/bioinformatics\/bty016<\/a><\/p>\n

*Raffenne J, Cros J. Molecular characterisation defines several subtypes of pancreatic ductal adenocarcinoma. [Article in French]. Bull Cancer<\/em><\/strong> 2018; 105(1):55-62. doi: 10.1016\/j.bulcan.2017.11.010<\/a>*<\/p>\n

*Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-<\/p>\n

* Tarantelli C, Bernasconi E, Gaudio E, et al. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open. 2018 Sep 26;3(6):e000387. doi: 10.1136\/esmoopen-2018-000387<\/a> <\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2016″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. <\/span>Blood<\/strong><\/em> 2015; 126(14): 1695\u20131698. doi: <\/span>10.1182\/blood-2015-05-647834<\/a><\/p>\n

*Bros\u00e9us J, Chen G, Hergalant S, et al. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget<\/strong><\/em> 2016; 7(51): 83987\u201384002. doi: 10.18632\/oncotarget.9793<\/a><\/p>\n

*Chicard M, Boyault S, Colmet Daage L et al. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clin Cancer Res<\/strong><\/em> 2016; 22(22):5564-5573. doi: 10.1158\/1078-0432.CCR-16-0500<\/a><\/p>\n

*Cros J, Hentic O, Rebours V, et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer<\/strong><\/em> 2016; 23(8):625-33. doi: 10.1530\/ERC-16-0117<\/a><\/p>\n

*Cros J, Moati E, Raffenne J, et al. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. Neuroendocrinology<\/strong><\/em> 2016; 103(5):495-9. doi: 10.1159\/000440724<\/a><\/p>\n

*Elizalde PV, Cordo Russo RI, Chervo MF et al. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer<\/strong><\/em> 2016;23(12):T243-T257. doi: org\/10.1530\/ERC-16-0360<\/a><\/p>\n

*Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol<\/strong><\/em> 2016; 27 (3): 390\u2013397. doi: org\/10.1093\/annonc\/mdv616<\/a> <\/p>\n

*Musa M, Radman M, Krisko A. Decreasing translation error rate in Escherichia coli increases protein function. BMC Biotechnol<\/strong><\/em> 2016; 16:28. doi: 10.1186\/s12896-016-0259-8<\/a><\/p>\n

*Nikoli\u0107 A , Peri\u0107 M , Ladouce R. Death by UVC Light Correlates with Protein Damage in Isogenic Human Tumor Cells: Primary Tumor SW480 versus its Metastasis SW620. J Proteomics Computational Biol<\/strong><\/em> 2016; 2(1):1-12<\/a><\/p>\n

*Peri\u0107 M, Bou Dib P, Dennerlein S, et al. Crosstalk between cellular compartments protects against proteotoxicity and extends lifespan. Sci Rep<\/strong><\/em> 2016; 6: 28751. doi: 10.1038\/srep28751<\/a><\/p>\n

*Sebbagh S, Roux J, Dreyer C, et al. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncol<\/strong><\/em> 2016; 55(9-10):1168-1174. doi: 10.1080\/0284186X.2016.1191670<\/a><\/p>\n

<\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2017″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Peri\u0107 M, Lovri\u0107 A, \u0160ari\u0107 A. TORC1-mediated sensing of chaperone activity alters glucose metabolism and extends lifespan. Aging Cell<\/strong><\/em> 2017;16(5):994-1005. doi: 10.1111\/acel.12623<\/a><\/p>\n

*Ros\u00e9us J, Mourah S, Ramstein G, et al. VEGF121<\/sub>, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. Oncotarget<\/em><\/strong>. 2017; 8(53):90808-90824. doi: 10.18632\/oncotarget.19385<\/a><\/p>\n

*Thieblemont C. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program<\/strong><\/em>. 2017; 2017(1): 371\u2013378. doi: 10.1182\/asheducation-2017.1.371<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2015″ _builder_version=”4.16″ link_option_url_new_window=”on” global_colors_info=”{}” open=”off”]<\/p>\n

*Cauchy F, Mebarki M, Albuquerque M, et al. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome. Gut<\/em><\/strong> 2015;64(9):1498-500. doi: 10.1136\/gutjnl-2015-310069<\/a><\/p>\n

*Conconi A1, Lobetti-Bodoni C2, Montoto S, et al. Life expectancy of young adults with follicular lymphoma. Ann Oncol<\/em><\/strong> 2015; 26(11):2317-22. doi: 10.1093\/annonc\/mdv376<\/a><\/p>\n

*Crescenzo R, Abate F, Lasorsa E et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell<\/em><\/strong> 2015; 27(4):516-32. doi: 10.1016\/j.ccell.2015.03.006<\/a><\/p>\n

*Eleveld TF, Oldridge DA2, Bernard V, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet<\/em><\/strong> 2015;47(8):864-71. doi: 10.1038\/ng.3333<\/a><\/p>\n

*Malouf GG, Tahara T, Paradis V, et al. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics.<\/em><\/strong> 2015; 10(9): 872\u2013881. doi: 10.1080\/15592294.2015.1076955<\/a><\/p>\n

*Neuzillet<\/span> <\/span>C, Tijeras-Raballand <\/sup>A, Cohen R, et al. Targeting the TGF\u03b2 pathway for cancer therapy.  Pharmacol Ther<\/strong><\/em>.<\/span> 2015; 147:22-31. doi: 10.1016\/j.pharmthera.2014.11.001<\/a><\/span><\/p>\n

*Neuzillet C, Couvelard A, Tijeras-Raballand A et al. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology<\/strong><\/em> 2015; 67(5):664-76. doi: 10.1111\/his.12691<\/a><\/p>\n

*Serova M, Tijeras-Raballand A, Dos Santos C, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget<\/em><\/strong>. 2015; 6(25):21614-27. doi: 10.18632\/oncotarget.4308<\/a> <\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2014″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*<\/span>Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev<\/em><\/strong> 2014;40(2):307-19. doi: 10.1016\/j.ctrv.2013.07.007<\/a><\/p>\n

*Bouska A1, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood<\/em><\/strong> 2014; 123(11):1681-90. doi: 10.1182\/blood-2013-05-500595<\/a><\/p>\n

*Collins A, Wojcik S, Frankel W, et al. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. <\/span>Ann Surg<\/em> Oncol<\/em><\/strong> <\/span>2014; 21(1):133-8. doi: 10.1245\/s10434-013-3240-y<\/a><\/span><\/p>\n

*Ghanem I, Riveiro ME, Paradis V, et al. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res<\/em><\/strong> 2014; 6(4):340-52<\/a><\/span>.<\/p>\n

*Malouf GG, Job S, Paradis V, et al. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology<\/strong><\/em> 2014; 59(6):2228-37. doi: 10.1002\/hep.27018<\/a><\/span><\/p>\n

*Malouf G, Taube J, Lu Y et al. “Architecture of Epigenetic Reprogramming Following Twist1-Mediated Epithelial-Mesenchymal Transition”. In  Cancer Cell Signaling: Targeting Signaling Pathways Toward Therapeutic Approaches to Cancer<\/em>. K Ayyanathan (Ed). Oakville, Canada. Apple Academic Press. 2014, p253. ISBN 9781771880671. <\/span><\/p>\n

*Neuzillet<\/span> C, de Gramont A, Tijeras-Raballand A, et al. Perspectives of TGF-\u03b2 inhibition in pancreatic and hepatocellular carcinomas. Oncotarget<\/span><\/em><\/strong> 2014; 5(1):78-94. doi: 10.18632\/oncotarget.1569<\/a><\/span><\/p>\n

*Zucca E, Stathis A, Bertoni F. The management of nongastric MALT lymphomas. Oncology<\/strong><\/em> (Williston Park). 2014;28(1):86-93<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2013″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Bertoni F, Li ZM, & Zucca E.  \u201cWhere do we stand in the genomics of lymphomas?\u201d In: Pfeffer U. (Ed) Cancer Genomics: Molecular Classification, Prognosis and Response Prediction. <\/strong>Springer-Verlag, 2013. ISBN 978-94-007-5842-1<\/p>\n

*Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma <\/em><\/strong>2013; 54(9):1908-14. doi: 10.3109\/10428194.2013.767454<\/a><\/p>\n

*Dings RP, Levine J, Brown SG, et al. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs<\/strong><\/em> 2013;31(5):1142-50. doi: 10.1007\/s10637-013-9932-0<\/a><\/p>\n

*Li ZM, Spagnuolo L, Mensah AA, et al. Gains of CCND3 <\/em>gene in ocular adnexal MALT lymphomas: an integrated analysis. Br J Haematol <\/em><\/strong>2013; 160 (5): 719-22. doi: 10.1111\/bjh.12161<\/a><\/p>\n

*Malouf GG, Taube JH, Lu Y, Roysarkar T et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol<\/em><\/strong> 2013; 14(12):R144. doi: 10.1186\/gb-2013-14-12-r144<\/a><\/p>\n

*Mian M, Rinaldi A, Mensah AA, et al.  Large genomic aberrations detected by SNP-array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Ann Oncol<\/em> <\/strong>2013; 23: 729-735. doi: 10.1093\/annonc\/mds646<\/a><\/p>\n

*Neuzillet C, Hammel P, Tijeras-Raballand A, et al.  Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev<\/em><\/strong> 2013 Jun;32(1-2):147-62. doi: 10.1007\/s10555-012-9396-2<\/a><\/p>\n

*Rinaldi A, Mensah AA, Kwee I, et al. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol<\/em><\/strong> 2013;163(2):194-204. doi: 10.1111\/bjh.12515<\/a><\/p>\n

*Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <\/span>Blood<\/em> <\/strong>2013; 121(8): 1403-1412. doi: <\/span>10.1182\/blood-2012-09-458265<\/a><\/p>\n

*Serova M, de Gramont A, Tijeras-Raballand A, et al.  Benchmarking effects of mTOR, PI3K, and dual PI3K\/Mtor inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol<\/strong><\/em>. 2013; 71(5):1297-307. doi: 10.1007\/s00280-013-2129-6<\/a><\/p>\n

*Taube JH1, Malouf GG, Lu E, Sphyris N et al. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep<\/em><\/strong>. 2013;3:2687. doi: 10.1038\/srep02687<\/a> <\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2011″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Lambiv WL1, Vassallo I, Delorenzi M et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol<\/em><\/strong> 2011; 13(7):736-47. doi: 10.1093\/neuonc\/nor036<\/a><\/p>\n

Burgess BL, Rao NP, Eskin A, et al. Characterization of three cell lines derived from fine needle biopsy of choroidal melanoma with metastatic outcome. Mol Vis. 2011 Feb 25;17:607-15<\/a><\/p>\n

McCannel TA, Burgess BL, Nelson SF, et al. Genomic identification of significant targets in ciliochoroidal melanoma. Invest Ophthalmol Vis Sci. 2011 May 9;52(6):3018-22. doi: 10.1167\/iovs.10-5864<\/a><\/span> <\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2012″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Agnelli L, Mereu E, Pellegrino E, et al. Identification of a three-gene model as a powerful diagnostic tool for the recognition of ALK negative ALCL. Blood <\/strong>2012; 120(6):1274-81. doi.org\/10.1182\/blood-2012-01-405555<\/a><\/p>\n

*Albert S, Hourseau M, Halimi C, et al.  Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol<\/em><\/strong> 2012;48(12):1263-71. doi: org\/10.1016\/j.oraloncology.2012.06.010<\/a><\/p>\n

*Delbaldo C, Faivre S, Dreyer C et al. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential. Ther Adv Med Oncol<\/em><\/strong> 2012; 4(1):9-18. doi: 10.1177\/1758834011428147<\/a><\/p>\n

*Dings RP, Miller MC, Nesmelova I, et al. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem<\/em><\/strong> 2012;55(11):5121-9. doi: 10.1021\/jm300014q<\/a><\/p>\n

*Li ZM, Rinaldi A, Cavalli A, et al. MYD88 somatic mutations in MALT lymphomas. Br J Haematol<\/em> <\/strong>2012; 158(5):662-4. doi: 10.1111\/j.1365-2141.2012.09176.x<\/a><\/p>\n

*Malouf GG, Brugi\u00e8res L, Le Deley MC, et al. Pure and mixed fibrolamellar hepatocellular carcinoma differs in their natural history and prognosis. Cancer<\/em>. <\/strong>2012; 15;118(20):4981-90. doi: 10.1002\/cncr.27520<\/a><\/p>\n

*Molinari F, Frattini M. KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem. Expert Rev Mol Diagn<\/em><\/strong> 2012;12(2):123-6. doi: 10.1586\/erm.11.94<\/a><\/p>\n

*Raymond E, Dreyer C, Faivre S. Targeting neuroendocrine tumor: mixing standard options with novel therapies. Target Oncol<\/strong><\/em> 2012; 7(3):151-2. doi: 10.1007\/s11523-012-0231-z<\/a><\/p>\n

*Raymond E, Ruszniewski P. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? Target Oncol<\/em><\/strong> 2012; 7(2):91-2. doi: 10.1007\/s11523-012-0222-0<\/a>.<\/p>\n

*Raymond E, Hammel P, Dreyer C, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol<\/strong><\/em> 2012; 7(2):117-25. doi: 10.1007\/s11523-012-0220-2<\/a><\/p>\n

*Rossi R, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med <\/strong><\/em>2012: 27;209(9):1537-51. doi: 10.1084\/jem.20120904<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2010″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*O’Toole D, Couvelard A, Rebours V, et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer<\/em><\/strong> 2010; 17(4):847-56. doi: 10.1677\/ERC-09-0204<\/a><\/p>\n

*Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature<\/em><\/strong>.<\/span> 2010; 467(7319):1114-7. doi: 10.1038\/nature09515<\/a><\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2007″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Chinot OL, Barri\u00e9 M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol<\/em><\/strong> 2007;25(12):1470-5. doi: 10.1200\/JCO.2006.07.4807<\/a><\/p>\n

*Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer<\/strong><\/em>. 2007; 5(6):379-85. doi.org\/10.3816\/CGC.2007.n.020<\/a> <\/span><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2006″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Colin C, Baeza N, Bartoli C, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene<\/em><\/strong> 2006; 25(19):2818-26. doi: org\/10.1038\/sj.onc.1209305<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2005″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med<\/em><\/strong>. 2005; 352(10):997-1003. doi: 10.1056\/NEJMoa043331<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”2008″ _builder_version=”4.16″ global_colors_info=”{}” open=”off”]<\/p>\n

*Chandarlapaty S, Sawai A, Ye Q, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res<\/em><\/strong>. 2008; 14(1):240-8. doi: 10.1158\/1078-0432.CCR-07-1667<\/a><\/span><\/p>\n

*<\/span>Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015-24. doi: 10.1200\/JCO.2007.15.7164<\/a> <\/span><\/p>\n

[\/et_pb_accordion_item][\/et_pb_accordion][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

*Cacciatore A, Shinde D, Musumeci C, et al. Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer. Nat Commun. 2024;15(1):6672. doi:10.1038\/s41467-024-50908-7.*Iseas S, Mariano G, Gros L, et al. Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances. Mol Diagn Ther. 2024;28(2):201-214. doi: 10.1007\/s40291-023-00692-9.*Cacciatore A, Albino D, […]<\/p>\n","protected":false},"author":9,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-694","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/pages\/694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/comments?post=694"}],"version-history":[{"count":85,"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/pages\/694\/revisions"}],"predecessor-version":[{"id":1717,"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/pages\/694\/revisions\/1717"}],"wp:attachment":[{"href":"https:\/\/www.fondationbarletta.org\/en\/wp-json\/wp\/v2\/media?parent=694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}